Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC-ALS: Early Phase 2 Trial of EPI-589 in ALS
jRCT2061210031Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EPI-589 in amyotrophic lateral sclerosis (ALS), sponsored by Sumitomo Pharma. Primary endpoint: Safety and tolerability. Started Oct 2021; status: completed.
02
Drugs
EPI-589
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2061210031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210031.